Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,728.50
Bid: 1,727.00
Ask: 1,728.00
Change: 0.00 (0.00%)
Spread: 1.00 (0.058%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London close: FTSE 100 at three-week high after policy meetings

Thu, 05th Sep 2013 17:03

A host of central-bank policy meetings, a dovish tone from Mario Draghi and the continued improvement in US economic data helped lift stocks higher on Thursday, with the FTSE 100 closing at levels not seen in three weeks.London's benchmark index ended the day up 57.7 points at 6,532.44, its highest level since August 14th when it finished at 6,587.43."European equities are enjoying the continued central-bank activism of low interest rates environment sticking around for the foreseeable future," said Market Strategist Ishaq Siddiqi from ETX Capital.The Bank of Japan, Bank of England and European Central Bank (ECB) all decided to keep interest rates on hold and current stimulus measures in place on Thursday. However, stocks extended gains in the afternoon after ECB President Mario Draghi struck a dovish tone in a press conference following the bank's decision, saying that the Governing Council had even discussed a rate cut at this month's meeting but decided against it. Draghi did however raise his expectations for Eurozone growth for this year.A barrage of US economic data came in better than expected this afternoon, supporting the call for the Federal Reserve to begin tapering asset purchases at its next meeting later this month - jobless claims fell more than forecasts, factory orders declined less than expected and the ISM non-manufacturing index smashed estimates.However, given that the Fed has explicitly said that the labour market is a key factor in its decision, analysts will be watching the August employment report - due out on Friday afternoon - very carefully. Consensus estimates are for a 180,000 increase in non-farm payrolls last month, up from the 162,000 gain in July. The unemployment rate is expected to remain unchanged at 7.4%, though this has already fallen speedily from 7.9% in January.Meanwhile, the G20 meeting which began in St Petersburg today was likely on the back of investors' minds, given that a potential US military strike in Syria is expected to be the hot topic amongst world leaders. Michael Hewson, Senior Market Analyst at CMC Markets, said: "while there may not be much in the way of fireworks we could well see a lot of tension, given the opposing views of the US and Russia, over the rationale for any type of intervention."FTSE 100: M&S leaps after HSBC upgradeHigh Street department store Marks & Spencer surged today after HSBC upgraded the stock from 'neutral' to 'overweight', saying it is the most operationally geared among its peers to play on the UK consumer recovery.Hotels group IHG was also a high riser after UBS raised its rating from 'neutral to 'buy' and added the stock to its 'Most Preferred' list. The Swiss bank highlighted alleviated concerns about pipeline after the company added more rooms in the first half and also pointed to improving growth in China and continued strength in the US.Decent August traffic statistics from airline peers easyJet and IAG over the last 24 hours have helped both stocks rebound today after falling heavily yesterday on the back of a profit warning from Ryanair, Europe's largest low-cost carrier.Banks were also performing well with Lloyds, Standard Chartered, HSBC, RBS and Barclays all registering decent gains. Lloyds was being helped higher by reports that the Treasury could delay the sale of its 39% stake until later this year because of ongoing tensions in the Middle East and the Fed's taper plan.Meanwhile, food groups Tate & Lyle and AB Foods were lower after Credit Suisse highlighted concerns about sugar prices falling sooner and more steeply than expected.Pharmaceuticals group GlaxoSmithKline was also in the red after announcing a setback on its potential new skin-cancer treatment during clinical trials.FTSE 100 - RisersPersimmon (PSN) 1,152.00p +3.69%Marks & Spencer Group (MKS) 494.90p +3.38%ITV (ITV) 174.60p +3.07%Lloyds Banking Group (LLOY) 74.77p +2.95%International Consolidated Airlines Group SA (CDI) (IAG) 299.40p +2.89%Kingfisher (KGF) 405.80p +2.86%GKN (GKN) 346.60p +2.70%Standard Chartered (STAN) 1,472.50p +2.58%Wolseley (WOS) 3,383.00p +2.52%Rolls-Royce Holdings (RR.) 1,147.00p +2.50%FTSE 100 - FallersTate & Lyle (TATE) 799.50p -1.60%Croda International (CRDA) 2,607.00p -1.25%GlaxoSmithKline (GSK) 1,652.50p -0.81%British Sky Broadcasting Group (BSY) 851.50p -0.76%Associated British Foods (ABF) 1,829.00p -0.65%G4S (GFS) 254.40p -0.62%Antofagasta (ANTO) 881.00p -0.56%Bunzl (BNZL) 1,365.00p -0.44%Aggreko (AGK) 1,599.00p -0.37%Admiral Group (ADM) 1,260.00p -0.32%FTSE 250 - RisersICAP (IAP) 400.00p +6.70%Dixons Retail (DXNS) 46.88p +5.92%Supergroup (SGP) 1,227.00p +5.87%Imagination Technologies Group (IMG) 279.30p +5.68%Tullett Prebon (TLPR) 382.40p +5.29%Home Retail Group (HOME) 152.50p +5.03%Halfords Group (HFD) 381.00p +4.01%Rentokil Initial (RTO) 107.50p +3.97%Hochschild Mining (HOC) 277.90p +3.89%Galliford Try (GFRD) 1,015.00p +3.73%FTSE 250 - FallersBumi (BUMI) 213.40p -2.87%Countrywide (CWD) 550.00p -2.65%BH Macro Ltd. EUR Shares (BHME) € 20.62 -2.51%Rank Group (RNK) 153.10p -2.48%Dairy Crest Group (DCG) 490.60p -2.17%Ted Baker (TED) 1,920.00p -2.14%esure Group (ESUR) 228.50p -1.93%International Public Partnerships Ltd. (INPP) 128.60p -1.83%NMC Health (NMC) 323.00p -1.79%Enterprise Inns (ETI) 143.40p -1.71%BC
More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.